FDA acceptance achieved by Greatbatch Medical thanks to help from Ceram

NewsGuard 100/100 Score

Ceram, the independent materials technology company, has recently helped Greatbatch Medical, providers of critical technologies used in medical devices, to gain FDA acceptance of its hydroxyapatite coating master file by providing all the necessary testing on the coating for a 510(k) implant submission.

In an effort to supply its French-produced coated devices marketed by its customers into the US market, Greatbatch Medical submitted a detailed hydroxyapatite coating master file to FDA in conjunction with the customer-submitted 510(k) submission. Ceram developed a comprehensive testing programme to supply sound and complete data and analysis to support the submission.

Working with implant manufacturers and bone replacement material suppliers, Ceram offers both a pre- and post-regulatory approval service to the medical device industry.

Dr Richard White, Head of Testing at Ceram, said:

“We are unique in that, thanks to our extensive analytical services, we can put together a complete testing regime for clients.  Our aim is to take the guesswork out of what is needed to gain regulatory approval, by using our experience to put together all the chemical, physical and microstructural testing in a bespoke package. We then deliver credible data with full documentation and ongoing technical support.

“We congratulate Greatbatch Medical on achieving FDA acceptance and believe that the whole process has highlighted the value of working so closely together.”

Valéry Barbour, Quality Assurance - Customer Relation Manager, at Greatbatch Medical said:

“I would like to thank all of the Ceram team that has worked on this file during the last few months for its great involvement in the project, strong expertise and excellent responsiveness.

Working closely together allowed us to develop a comprehensive testing programme to fulfil FDA requirements for the submission of a hydroxyapatite coating master file.

“Ceram’s responsiveness to our questions really moved along the review of the file by FDA and we have really appreciated it! It was a challenging key milestone that we have successfully managed thanks to our new partnership.”

For more information about Ceram’s regulatory approval service visit www.ceram.com/reg-approval

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates